Three-batch Process Validation Lives on in Europe
This article was originally published in The Gold Sheet
Executive Summary
The European Medicines Agency’s final process validation guidance fails to fully incorporate science- and risk-based approaches, asserts Europe’s pharmaceutical industry. The EMA is still collecting comments on the revised Annex 15 that covers the qualification and validation of facilities used in manufacturing.